Back to top

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00. Iovance Bioth...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Iovance Biotherapeutics, Inc. (IOVA)